+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharmacovigilance Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • PDF Icon

    Report

  • 149 Pages
  • August 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5641391
Description Jump to:
The pharmacovigilance (phv) market is anticipated to grow at a compound annual growth rate of 13.5% for the forecasted period (2022-2030). As the world's population ages, chronic diseases have increased; and more adverse drug reactions mean more pharmacovigilance. Pharmacovigilance (drug safety) is the healthcare industry's effort to ensure that pharmaceutical companies' claims are accurate and supported by scientific evidence. This report covers all the quantitative and qualitative aspects of pharmacovigilance market and also talks about its key drivers, the challenges it faces, the growth opportunities present in the market, and its future prospects.

Post Marketing Surveillance Phase Takes the Largest Slice

The market has been segmented on basis of Clinical Trial Phases, Service Providers, End Users, Methods, and Regional Basis. On the basis of Clinical Trials, Phase IV i.e. Post Marketing Surveillance Phase has a presiding share of about 75.6% for the year 2020 whereas On the basis of Service Provider, Contract Outsourcing has a presiding share of about 59.2%. Spontaneous Reporting has a dominant share of 30.3% for the year 2020 because of its usefulness in detecting new, serious and rare adverse drug reaction cases and moreover it is an efficient and inexpensive method of reporting ADRs. After Spontaneous Reporting, Cohort Event Monitoring is expected to show growth exponentially over a forecast period. While viewing Phv Market on basis of therapeutic areas, oncology (The study and Treatment of Tumours) dominates the market with a share of about 26.5% whereas while viewing it on basis of end Users, pharmaceuticals dominates the market with a share of 42.6%.

Pharmacovigilance Market: Drivers and Challenges

The surge in cases of Adverse drug reaction (ADR), the increasing occurrence of Chronic Diseases (Diabetes, Cancer, etc.) which in turn lead to increased drug consumption are a few of the main underlying forces driving the growth of the Phv Market. 5% of hospitalizations in Europe and the U.S.in the year 2019 were due to adverse drug reaction cases. Iatrogenic disease is the most common disease caused due to adverse drug reactions.

According to a study by Tufts University, 40% of Adverse Drug Events are never reported by Healthcare Professionals. Another major problem in Spontaneous Reporting of Adverse drug events (ADE) is misreporting and miscoding of reports. The data mentioned in reports under the fields of dosage, formulation type, time, and length of exposure to ADE is not clearly stated.

Pharmacovigilance Market: Key Player and Market

For the year 2020, North America dominated the Pharmacovigilance Market with a fair share of about 34% due to the presence of key pharmaceuticals and MDMs (Medical Device Players) whereas the Asia Pacific is anticipated to have a compound annual growth rate of 13.5% attributable to its accessibility of various outsourcing organizations. Industry leaders are targeting on developing research and development activities, new product launches, collaborating with leading Pharmaceutical companies in order to spread awareness about proper use of medicines and having access to medical information.Few of the pharmacovigilance market’s key players are- BoehringerIngelheim, Bristol-Myers Squibb, Clinquest Group B.V., EcronAcunova Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline, HCL Technologies, Accenture, Cognizant, IBM Corporation, Wipro Limited.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. Key data points that enables the estimation of Pharmacovigilance market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Pharmacovigilance market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Pharmacovigilance market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Pharmacovigilance market?
  • Which is the largest regional market for Pharmacovigilance market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Pharmacovigilance market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Pharmacovigilance market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Pharmacovigilance Market
2.2. Global Pharmacovigilance Market, By Clinical Trial Phase, 2021 (US$ Million)
2.3. Global Pharmacovigilance Market, By Type of Method, 2021 (US$ Million)
2.4. Global Pharmacovigilance Market, By Type of End User, 2021 (US$ Million)
2.5. Global Pharmacovigilance Market, By Type of Service Provider, 2021 (US$ Million)
2.6. Global Pharmacovigilance Market, By Therapeutic Area, 2021 (US$ Million)
2.7. Global Pharmacovigilance Market, By Geography, 2021 (US$ Million)
2.8. Global Pharmacovigilance Market, By Impact of COVID-19, 2020 (US$ Million)
2.9. Key Investment Proposition by Geography, 2021
2.10. Competitive Analysis
2.11. Key Industry Strategies
2.12. Tier Analysis 2021 Versus 2030
2.13. Key Buying Criteria
2.14. Key Case Reports
2.15. Scenario Analysis
2.16. Optimistic estimates and analysis
2.17. Realistic estimates and analysis
2.18. Pessimistic estimates and analysis
2.19. Market Profiling
2.20. Sales and Marketing Plan
2.21. Heptalysis Analysis
2.22. Critical Investigation of Business Problems Through Five Whys Root Cause Analysis & Relevant Solutions
2.23. Top Market Conclusions
2.24. Strategic Recommendations
3. Pharmacovigilance Market: Business Outlook & Market Dynamics
3.1. Introduction
3.2. Global Pharmacovigilance Market Value, 2020-2030, (US$ Million)
3.3. Key Trends Analysis
3.4. Market Dynamics
3.4.1. Market Drivers
3.4.2. Market Restraints
3.4.3. Key Challenges
3.4.4. Key Opportunities
3.5. Impact Analysis of Drivers and Restraints
3.6. See-Saw Analysis
3.7. Attractive Investment Proposition
3.8. Porter’s Five Force Model
3.8.1. Supplier Power
3.8.2. Buyer Power
3.8.3. Threat Of Substitutes
3.8.4. Threat Of New Entrants
3.8.5. Competitive Rivalry
3.9. PESTEL Analysis
3.9.1. Political Landscape
3.9.2. Economic Landscape
3.9.3. Technology Landscape
3.9.4. Legal Landscape
3.9.5. Social Landscape
3.10. Competitive Landscape
3.10.1. Market Positioning of Key Pharmacovigilance Market Vendors
3.10.2. Strategies Adopted by Pharmacovigilance Market Vendors
4. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
4.3.1. Preclinical Animal Toxicity
4.3.2. Clinical Trial Phase I
4.3.3. Clinical Trial Phase II
4.3.4. Clinical Trial Phase III
4.3.5. Post Marketing Surveillance
5. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Spontaneous Reporting
5.3.2. Intensified Adverse Drug Reaction Reporting
5.3.3. Targeted Reporting
5.3.4. Cohort Event Monitoring
5.3.5. EHR Monitoring
6. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. In-House
6.3.2. Contract Outsourcing
7. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2021 Versus 2030
7.3. Market Segmentation
7.3.1. Hospitals
7.3.2. Pharmaceutical Companies
7.3.3. Others
8. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Growth & Revenue Analysis: 2021 Versus 2030
8.3. Market Segmentation
8.3.1. Oncology
8.3.2. Cardiology
8.3.3. Respiratory Systems
8.3.4. Others
9. North America Pharmacovigilance Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
9.3. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
9.4. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
9.5. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
9.6. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
9.7.Pharmacovigilance Market: By Region, 2020-2030, USD (Million)
9.7.1.North America
9.7.1.1. U.S.
9.7.1.1.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
9.7.1.1.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
9.7.1.1.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
9.7.1.1.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
9.7.1.1.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
9.7.1.2. Canada
9.7.1.2.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
9.7.1.2.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
9.7.1.2.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
9.7.1.2.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
9.7.1.2.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
9.7.1.3. Rest of North America
9.7.1.3.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
9.7.1.3.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
9.7.1.3.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
9.7.1.3.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
9.7.1.3.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
10. UK and European Union Pharmacovigilance Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
10.3. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
10.4. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
10.5. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
10.6. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
10.7.Pharmacovigilance Market: By Region, 2020-2030, USD (Million)
10.7.1.UK and European Union
10.7.1.1. UK
10.7.1.1.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
10.7.1.1.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
10.7.1.1.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
10.7.1.1.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
10.7.1.1.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
10.7.1.2. Germany
10.7.1.2.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
10.7.1.2.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
10.7.1.2.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
10.7.1.2.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
10.7.1.2.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
10.7.1.3. Spain
10.7.1.3.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
10.7.1.3.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
10.7.1.3.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
10.7.1.3.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
10.7.1.3.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
10.7.1.4. Italy
10.7.1.4.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
10.7.1.4.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
10.7.1.4.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
10.7.1.4.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
10.7.1.4.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
10.7.1.5. France
10.7.1.5.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
10.7.1.5.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
10.7.1.5.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
10.7.1.5.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
10.7.1.5.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
10.7.1.6. Rest of Europe
10.7.1.6.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
10.7.1.6.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
10.7.1.6.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
10.7.1.6.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
10.7.1.6.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
11. Asia Pacific Pharmacovigilance Market, 2020-2030, USD (Million)
11.1. Market Overview
11.2. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
11.3. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
11.4. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
11.5. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
11.6. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
11.7.Pharmacovigilance Market: By Region, 2020-2030, USD (Million)
11.7.1.Asia Pacific
11.7.1.1. China
11.7.1.1.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
11.7.1.1.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
11.7.1.1.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
11.7.1.1.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
11.7.1.1.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
11.7.1.2. Japan
11.7.1.2.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
11.7.1.2.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
11.7.1.2.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
11.7.1.2.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
11.7.1.2.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
11.7.1.3. India
11.7.1.3.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
11.7.1.3.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
11.7.1.3.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
11.7.1.3.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
11.7.1.3.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
11.7.1.4. Australia
11.7.1.4.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
11.7.1.4.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
11.7.1.4.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
11.7.1.4.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
11.7.1.4.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
11.7.1.5. South Korea
11.7.1.5.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
11.7.1.5.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
11.7.1.5.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
11.7.1.5.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
11.7.1.5.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
11.7.1.6. Rest of Asia Pacific
11.7.1.6.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
11.7.1.6.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
11.7.1.6.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
11.7.1.6.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
11.7.1.6.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
12. Latin America Pharmacovigilance Market, 2020-2030, USD (Million)
12.1. Market Overview
12.2. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
12.3. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
12.4. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
12.5. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
12.6. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
12.7.Pharmacovigilance Market: By Region, 2020-2030, USD (Million)
12.7.1.Latin America
12.7.1.1. Brazil
12.7.1.1.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
12.7.1.1.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
12.7.1.1.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
12.7.1.1.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
12.7.1.1.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
12.7.1.2. Mexico
12.7.1.2.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
12.7.1.2.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
12.7.1.2.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
12.7.1.2.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
12.7.1.2.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
12.7.1.3. Rest of Latin America
12.7.1.3.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
12.7.1.3.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
12.7.1.3.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
12.7.1.3.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
12.7.1.3.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
13. Middle East and Africa Pharmacovigilance Market, 2020-2030, USD (Million)
13.1. Market Overview
13.2. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
13.3. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
13.4. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
13.5. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
13.6. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
13.7.Pharmacovigilance Market: By Region, 2020-2030, USD (Million)
13.7.1.Middle East and Africa
13.7.1.1. GCC
13.7.1.1.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
13.7.1.1.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
13.7.1.1.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
13.7.1.1.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
13.7.1.1.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
13.7.1.2. Africa
13.7.1.2.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
13.7.1.2.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
13.7.1.2.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
13.7.1.2.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
13.7.1.2.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
13.7.1.3. Rest of Middle East and Africa
13.7.1.3.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
13.7.1.3.2. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
13.7.1.3.3. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
13.7.1.3.4. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
13.7.1.3.5. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
14. Company Profile
14.1. Accenture
14.1.1. Company Overview
14.1.2. Financial Performance
14.1.3. Product Portfolio
14.1.4. Strategic Initiatives
14.2. BoehringerIngelheim
14.2.1. Company Overview
14.2.2. Financial Performance
14.2.3. Product Portfolio
14.2.4. Strategic Initiatives
14.3. Bristol-Myers Squibb
14.3.1. Company Overview
14.3.2. Financial Performance
14.3.3. Product Portfolio
14.3.4. Strategic Initiatives
14.4. Clinquest Group B.V.
14.4.1. Company Overview
14.4.2. Financial Performance
14.4.3. Product Portfolio
14.4.4. Strategic Initiatives
14.5. Cognizant Technology Solutions Corporation
14.5.1. Company Overview
14.5.2. Financial Performance
14.5.3. Product Portfolio
14.5.4. Strategic Initiatives
14.6. EcronAcunova Ltd.
14.6.1. Company Overview
14.6.2. Financial Performance
14.6.3. Product Portfolio
14.6.4. Strategic Initiatives
14.7. F. Hoffmann-La Roche Ltd.
14.7.1. Company Overview
14.7.2. Financial Performance
14.7.3. Product Portfolio
14.7.4. Strategic Initiatives
14.8. GlaxoSmithKline
14.8.1. Company Overview
14.8.2. Financial Performance
14.8.3. Product Portfolio
14.8.4. Strategic Initiatives
14.9. HCL Technologies
14.9.1. Company Overview
14.9.2. Financial Performance
14.9.3. Product Portfolio
14.9.4. Strategic Initiatives
14.10. IBM Corporation
14.10.1. Company Overview
14.10.2. Financial Performance
14.10.3. Product Portfolio
14.10.4. Strategic Initiatives
List of Figures
Figure 1 Global Pharmacovigilance Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Pharmacovigilance Market: Quality Assurance
Figure 5 Global Pharmacovigilance Market, By Clinical Trial Phase, 2021
Figure 6 Global Pharmacovigilance Market, By Type of Method, 2021
Figure 7 Global Pharmacovigilance Market, By Type of End User, 2021
Figure 8 Global Pharmacovigilance Market, By Type of Service Provider, 2021
Figure 9 Global Pharmacovigilance Market, By Therapeutic Area, 2021
Figure 10 Global Pharmacovigilance Market, By Geography, 2021
Figure 11 Market Geographical Opportunity Matrix - Global Pharmacovigilance Market, 2021
Figure 12 Market Positioning of Key Pharmacovigilance Market Players, 2021
Figure 13 Global Pharmacovigilance Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 14 Porters Five Force Model - Current, Midterm and Long Term Perspective
Figure 15 See Saw Analysis
Figure 16 PETEL Analysis
Figure 17 Key Buying Criteria: Current and Long-Term Perspective
Figure 18 Global Pharmacovigilance Market, Scenario Analysis, 2020 to 2030 (US$ Million)
Figure 19 Heptalysis Analysis: Global Pharmacovigilance Market
Figure 20 Five Whys Analysis
Figure 21 Global Pharmacovigilance Market, By Clinical Trial Phase, 2021 Vs 2030, %
Figure 22 Global Pharmacovigilance Market, By Type of Method, 2021 Vs 2030, %
Figure 23 Global Pharmacovigilance Market, By Type of End User, 2021 Vs 2030, %
Figure 24 Global Pharmacovigilance Market, By Type of Service Provider, 2021 Vs 2030, %
Figure 25 Global Pharmacovigilance Market, By Therapeutic Area, 2021 Vs 2030, %
Figure 26 U.S. Pharmacovigilance Market (US$ Million), 2020-2030
Figure 27 Canada Pharmacovigilance Market (US$ Million), 2020-2030
Figure 28 Rest of North America Pharmacovigilance Market (US$ Million), 2020-2030
Figure 29 UK Pharmacovigilance Market (US$ Million), 2020-2030
Figure 30 Germany Pharmacovigilance Market (US$ Million), 2020-2030
Figure 31 Spain Pharmacovigilance Market (US$ Million), 2020-2030
Figure 32 Italy Pharmacovigilance Market (US$ Million), 2020-2030
Figure 33 France Pharmacovigilance Market (US$ Million), 2020-2030
Figure 34 Rest of Europe Pharmacovigilance Market (US$ Million), 2020-2030
Figure 35 China Pharmacovigilance Market (US$ Million), 2020-2030
Figure 36 Japan Pharmacovigilance Market (US$ Million), 2020-2030
Figure 37 India Pharmacovigilance Market (US$ Million), 2020-2030
Figure 38 Australia Pharmacovigilance Market (US$ Million), 2020-2030
Figure 39 South Korea Pharmacovigilance Market (US$ Million), 2020-2030
Figure 40 Rest of Asia Pharmacovigilance Market (US$ Million), 2020-2030
Figure 41 Brazil Pharmacovigilance Market (US$ Million), 2020-2030
Figure 42 Mexico Pharmacovigilance Market (US$ Million), 2020-2030
Figure 43 Rest of Latin America Pharmacovigilance Market (US$ Million), 2020-2030
Figure 44 GCC Pharmacovigilance Market (US$ Million), 2020-2030
Figure 45 Africa Pharmacovigilance Market (US$ Million), 2020-2030
Figure 46 Rest of Middle East and Africa Pharmacovigilance Market (US$ Million), 2020-2030
List of Tables
Table 1 Global Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 2 Global Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 3 Global Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 4 Global Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 5 Global Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 6 North America Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 7 North America Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 8 North America Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 9 North America Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 10 North America Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 11 U.S. Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 12 U.S. Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 13 U.S. Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 14 U.S. Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 15 U.S. Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 16 Canada Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 17 Canada Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 18 Canada Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 19 Canada Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 20 Canada Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 21 Rest of North America Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 22 Rest of North America Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 23 Rest of North America Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 24 Rest of North America Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 25 Rest of North America Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 26 UK and European Union Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 27 UK and European Union Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 28 UK and European Union Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 29 UK and European Union Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 30 UK and European Union Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 31 UK Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 32 UK Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 33 UK Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 34 UK Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 35 UK Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 36 Germany Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 37 Germany Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 38 Germany Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 39 Germany Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 40 Germany Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 41 Spain Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 42 Spain Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 43 Spain Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 44 Spain Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 45 Spain Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 46 Italy Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 47 Italy Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 48 Italy Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 49 Italy Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 50 Italy Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 51 France Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 52 France Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 53 France Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 54 France Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 55 France Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 56 Rest of Europe Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 57 Rest of Europe Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 58 Rest of Europe Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 59 Rest of Europe Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 60 Rest of Europe Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 61 Asia Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 62 Asia Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 63 Asia Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 64 Asia Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 65 Asia Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 66 China Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 67 China Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 68 China Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 69 China Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 70 China Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 71 Japan Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 72 Japan Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 73 Japan Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 74 Japan Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 75 Japan Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 76 India Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 77 India Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 78 India Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 79 India Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 80 India Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 81 Australia Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 82 Australia Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 83 Australia Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 84 Australia Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 85 Australia Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 86 South Korea Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 87 South Korea Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 88 South Korea Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 89 South Korea Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 90 South Korea Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 91 Latin America Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 92 Latin America Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 93 Latin America Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 94 Latin America Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 95 Latin America Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 96 Brazil Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 97 Brazil Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 98 Brazil Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 99 Brazil Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 100 Brazil Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 101 Mexico Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 102 Mexico Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 103 Mexico Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 104 Mexico Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 105 Mexico Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 106 Rest of Latin America Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 107 Rest of Latin America Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 108 Rest of Latin America Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 109 Rest of Latin America Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 110 Rest of Latin America Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 111 Middle East and Africa Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 112 Middle East and Africa Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 113 Middle East and Africa Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 114 Middle East and Africa Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 115 Middle East and Africa Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 116 GCC Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 117 GCC Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 118 GCC Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 119 GCC Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 120 GCC Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 121 Africa Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 122 Africa Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 123 Africa Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 124 Africa Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 125 Africa Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
Table 126 Rest of Middle East and Africa Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
Table 127 Rest of Middle East and Africa Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
Table 128 Rest of Middle East and Africa Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
Table 129 Rest of Middle East and Africa Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
Table 130 Rest of Middle East and Africa Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)

Companies Mentioned

  • Accenture
  • BoehringerIngelheim
  • Bristol-Myers Squibb
  • Clinquest Group B.V.
  • Cognizant Technology Solutions Corporation
  • EcronAcunova Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline
  • HCL Technologies
  • IBM Corporation

Related Topics

Related Reports

Pharmacovigilance Market Size, Share & Trends Analysis Report By Service Provider (In-house, Contract Outsourcing), By Product Life Cycle, By Therapeutic Area, By Process Flow, By End-Use, By Type, And Segment Forecasts, 2023-2030 - Product Image

Pharmacovigilance Market Size, Share & Trends Analysis Report By Service Provider (In-house, Contract Outsourcing), By Product Life Cycle, By Therapeutic Area, By Process Flow, By End-Use, By Type, And Segment Forecasts, 2023-2030

  • Report
  • 298 Pages
  • Global
From
Global Pharmacovigilance Market by Type (Contract Outsourcing, In-house), Clinical Trial (Phase I, Phase II, Phase III), Function, End-User - Forecast 2024-2030 - Product Image

Global Pharmacovigilance Market by Type (Contract Outsourcing, In-house), Clinical Trial (Phase I, Phase II, Phase III), Function, End-User - Forecast 2024-2030

  • Report
  • 191 Pages
  • Global
From
Global Pharmacovigilance & Drug Safety Software Market by Product (Adverse Event Reporting Software, Drug Safety Audits Software, Fully Integrated Software), Clinical Trial (Phase I, Phase II, Phase III), Distribution, End User - Forecast 2023-2030 - Product Image

Global Pharmacovigilance & Drug Safety Software Market by Product (Adverse Event Reporting Software, Drug Safety Audits Software, Fully Integrated Software), Clinical Trial (Phase I, Phase II, Phase III), Distribution, End User - Forecast 2023-2030

  • Report
  • 193 Pages
  • Global
From
Pharmacovigilance Market Growth Analysis Report - Latest Trends, Driving Factors and Key Players Research to 2030 - Product Image

Pharmacovigilance Market Growth Analysis Report - Latest Trends, Driving Factors and Key Players Research to 2030

  • Report
  • 146 Pages
  • Global
From
Pharmacovigilance Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 - Product Image

Pharmacovigilance Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • Report
  • 147 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.